MDNA Life Sciences Inc. (MDNA), the molecular diagnostics company revolutionizing the development of liquid biopsy biomarkers based on the mitochondrial genome, announced today the that the Mitomic® Prostate Test (MPT™) is ready for release in the UK.
MDNA Life Sciences Inc. (MDNA), the molecular diagnostics company revolutionizing the development of liquid biopsy biomarkers based on the mitochondrial genome, announced today that it has agreed a licensing deal with Aspire Pharma Ltd. (Aspire) in the UK for the Mitomic® Prostate Test (MPT™). On the heels of recent news that MDNA’s CE marked MPT™ Real-Time PCR kit is now commercially available, this is the first international partner to be announced by MDNA and is the start of the global roll-out of MPT™through a growing network of distribution partners.
MDNA Life Sciences has entered into an exclusive license agreement with LabCorp® (LH) to develop and commercialize a non-invasive test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.
Continue reading “MDNA Life Sciences Announces Exclusive License Agreement with LabCorp®”
A single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA “grey zone”.
MDNA Life Sciences announces that it has entered into an exclusive license agreement with its first international commercial partner.